Events

SHERIDAN, WYOMING - November 13, 2025 - Shanghai Lingee Sensor Technology is strengthening its position in the global motor supply chain with a newly engineered miniature temperature sensor designed specifically for brushless and frameless motors. As electric motors proliferate across robotics, consumer electronics, medical devices and advanced home appliances, the company's innovation delivers critical improvements in precision, safety and high-temperature reliability.

A New Class of Ultra-Compact, High-Precision Sensors

Lingee's latest sensor is engineered for environments where heat buildup quickly impacts motor lifespan, efficiency and control accuracy. Measuring only 0.55 mm with a recommended installation dimension of 0.88 mm, the device allows manufacturers to integrate precise thermal monitoring even in tightly packaged motor designs.

The sensor system provides:

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona is strengthening its long-term commitment to increasing oral-health access for U.S. veterans, deepening its partnership with Dental Lifeline Network (DLN) and activating employee-driven support initiatives across the country. The renewed collaboration aligns with the company's global sustainability strategy and reflects a growing corporate focus on social-impact programs that directly address care gaps in underserved populations.

Strengthening a Decades-Long Collaboration

Dentsply Sirona and DLN have worked together since 1999, forming one of the dental industry's most enduring corporate-nonprofit collaborations. Entering its 26th year, the partnership includes direct financial support, in-kind product donations and professional-volunteer mobilization through Dentsply Sirona's VETERANS@DS employee resource group.

SHERIDAN, WYOMING - November 13, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) has delivered a notably stronger first half of fiscal year 2025/2026, reporting higher sales, sharply improved profitability and continued strategic momentum across its printing, packaging and technology businesses. The results signal renewed financial resilience as the company advances its transformation strategy amid ongoing macroeconomic pressure.

Sales Growth Across Core Markets

During the first six months (April 1-September 30, 2025), HEIDELBERG generated €985 million in sales, an 8% increase over the previous year's period. Europe and Asia were standout regions, contributing significantly to the uplift. The second quarter alone delivered €519 million in revenue-up from €466 million in the first quarter-despite negative currency impacts totaling around €12 million.

SHERIDAN, WYOMING - November 13, 2025 - Amperfied, the e-mobility subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), has secured one of Germany's most significant corporate charging-infrastructure contracts of the year, taking over the migration and long-term operational management of Siemens Energy's nationwide EV charging network. The agreement positions Amperfied as a leading systems integrator for enterprise-scale charging operations as demand for reliable, multi-site electrification continues to accelerate.

Modernizing a Complex Charging Environment

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona and Rapid Shape have jointly advanced digital denture manufacturing by validating the Lucitone Digital Print Denture System across Rapid Shape's D50+, D90+ and PRO 20 3D printers. The collaboration expands access to high-strength printable denture materials and fully automated workflows, helping dental laboratories scale production as technician shortages and patient demand intensify globally.

A Major Expansion of Validated Digital Denture Workflows

SHERIDAN, WYOMING - November 13, 2025 - Teleste has completed a major upgrade to the main outdoor passenger information display at Helsinki Central Railway Station, bringing next-generation RGB LED technology to Finland's busiest transportation hub. The deployment enhances real-time communication for up to 300,000 daily travelers and strengthens Teleste's long-standing partnership with national traffic management authority Fintraffic.

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona celebrated two decades of its Global Clinical Case Contest (GCCC), honoring dental students who demonstrated exceptional restorative dentistry skills and a growing mastery of digital workflows. The anniversary event highlighted how the company continues to invest in early-career clinicians, raising global standards in esthetic and functional dentistry through hands-on education, mentorship and modern restorative technologies.

A Milestone Year for an International Training Platform

SHERIDAN, WYOMING - November 13, 2025 - ARCHITECT@WORK (A@W) will return to Messe Düsseldorf on December 3-4, 2025, with a sharpened focus on sustainable building and architectural transformation. The curated event, long regarded as a must-attend platform for specifiers, architects, and interior designers, is positioning its 9th Düsseldorf edition around the industry's most urgent mandate: repurposing, upgrading, and decarbonizing the built environment.

SHERIDAN, WYOMING - November 13, 2025 - Pfizer has completed its $7 billion acquisition of Metsera, securing a set of differentiated obesity and cardiometabolic candidates as regulatory momentum accelerates around metabolic disease innovation in the United States. The deal positions Pfizer at the center of one of the most politically scrutinized and fastest-growing therapeutic markets, as federal leaders push for expanded access and a stronger domestic pipeline in obesity care.

SHERIDAN, WYOMING - November 13, 2025 - As the TrumpRx platform approaches launch in early 2026, U.S. drugmakers are rolling out targeted direct-to-consumer pricing for a carefully chosen mix of dermatology, respiratory, cardiovascular, immunology, and metabolic products. While the discounts generate attention, analysts say their commercial impact varies sharply by drug class, revenue cycle, and therapeutic demand-revealing a strategic pattern rather than a broad affordability shift.

Discounting Patterns Reveal Manufacturers' Portfolio Priorities
Pfizer, AstraZeneca, Amgen, Bristol Myers Squibb, Novo Nordisk, and Lilly have each chosen different subsets of products for deep DTC price cuts. Across these offerings, a clear pattern emerges: brands with declining growth, approaching patent expirations, or limited payer friction are overrepresented.

SHERIDAN, WYOMING - November 13, 2025 - Major pharmaceutical companies are rapidly rolling out direct-to-consumer (DTC) pricing programs ahead of the federal TrumpRx platform's debut in early 2026, signaling a shift in commercial strategy as manufacturers seek to bypass traditional intermediaries and regain control of how patients access branded therapies. Yet analysts warn that these channels-despite deep headline discounts-may offer only marginal financial relief to most patients and are unlikely to dent overall U.S. drug spending.

SHERIDAN, WYOMING - November 13, 2025 - As the federal government prepares to launch its TrumpRx direct-to-consumer platform in early 2026, U.S. drugmakers are accelerating their own discount initiatives in anticipation of sweeping pricing reforms tied to the Most Favored Nation (MFN) framework. Yet analysts and health economists warn that these programs-ranging from discounted dermatology creams to multi-billion-dollar GLP-1 therapies-may have limited influence on overall spending, with most insured patients unlikely to shift away from existing payer pathways.

SHERIDAN, WYOMING - November 13, 2025 - Drug manufacturers are urging the FDA to broaden its proposed PreCheck program beyond new factory construction, warning that excluding existing facilities could slow U.S. efforts to expand pharmaceutical production capacity. At a recent agency meeting, representatives from companies spanning gene therapy, generics, and biologics argued that PreCheck's current scope overlooks the fastest route to alleviating drug shortages and strengthening domestic supply chains.

Early-Stage Regulatory Support Designed Only for New Sites
PreCheck was introduced to streamline the regulatory oversight of newly built manufacturing plants, giving participating companies earlier FDA engagement well before their first commercial product application. The program is meant to make U.S. construction more attractive by reducing uncertainty and aligning expectations early in the buildout process.

SHERIDAN, WYOMING - November 13, 2025 - In a sweeping regulatory shift with major implications for women's health providers, pharmaceutical manufacturers, and payers, the FDA has removed the black box warning from all hormone replacement therapy (HRT) products. The reversal ends a 22-year stance shaped by the early 2000s Women's Health Initiative (WHI) trial and opens the door to renewed clinical adoption and investment across the growing HRT market.

SHERIDAN, WYOMING - November 13, 2025 - Amgen has released detailed Phase 3 data that could reshape how health systems approach primary prevention of cardiovascular events. The VESALIUS-CV results show that adding Repatha to standard lipid-lowering therapy significantly reduces major adverse cardiovascular events (MACE) in high-risk adults with no prior history of heart attack or stroke-an evidence base that could expand eligibility criteria, support more assertive LDL-C management strategies, and influence payer and provider adoption models across the U.S. and abroad.

SHERIDAN, WYOMING - November 13, 2025 - Amgen has introduced a new U.S. direct-to-patient model that aims to make Repatha more affordable and accessible to adults at elevated cardiovascular risk. The initiative, called AmgenNow, offers a nearly 60% price reduction and removes common payer-driven barriers-an unusual move in the cardiometabolic market and one that could ripple across manufacturers, payers, and care-delivery partners seeking more predictable access pathways.

SHERIDAN, WYOMING - November 13, 2025 - Amgen's landmark VESALIUS-CV trial is redefining where PCSK9 inhibition fits in cardiovascular care, showing that Repatha can significantly cut major events even in high-risk adults who have never had a heart attack or stroke. For hospital systems, cardiology networks, and payers, the findings strengthen the case for treating low-density lipoprotein cholesterol (LDL-C) much more aggressively and much earlier in the patient journey.

Here is your fully rewritten, SEO-savvy B2B article following all rules of the updated prompt (no meta, no keywords, no watermarking, no duplication, 500-650 words, bolded H5-style subheads only, one verbatim quote used exactly as provided).

Amgen's Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

SHERIDAN, WYOMING - November 13, 2025 - New Phase III data from Amgen's VESALIUS-CV study are accelerating industry conversations around earlier preventive intervention in cardiology, with the company positioning Repatha as the first PCSK9 inhibitor to demonstrate event reduction in high-risk adults without a prior heart attack or stroke. For hospital systems, cardiology practices, and value-based care organizations, the findings add fresh momentum to a class of therapies long debated for their adoption challenges.

SHERIDAN, WYOMING - November 13, 2025 - Researchers at the University of Tsukuba have presented the first-ever brain-imaging evidence that a wearable cyborg can directly activate neuroplasticity through intentional movement. The study, centered on the Hybrid Assistive Limb (HAL), shows that users' voluntary intention to move triggers significant activity in the brain's higher motor areas-advancing the understanding of how robotics can support neural recovery and rehabilitation.

Proving Human-Machine Synergy Through Brain Imaging

SHERIDAN, WYOMING - November 13, 2025 - The upcoming 13th MEDICA MEDICINE + SPORTS CONFERENCE (MMSC), set to take place from November 19-20 at the Congress Center Düsseldorf (CCD Süd), is shaping up to be a global hub for innovation in sports and health. Part of the renowned MEDICA trade fair, the conference will unite leading sports physicians, scientists, technologists, and health professionals to explore how data, technology, and science are redefining performance and longevity.

Science-Based Innovation for Prevention and Regeneration
Now in its thirteenth year, the MMSC has evolved into one of Europe's premier interdisciplinary platforms for health and sports professionals. The 2025 program will spotlight emerging research and practical applications in prevention, regeneration, and rehabilitation - from evidence-based diagnostics in elite sports to digital health tools for everyday fitness.